Clinical Trial Update: Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects [Phase 4]

View source ↗

Summary

Phase 4 trial update on steady-state pharmacokinetics of rifaximin 550 mg tablets in healthy and severely hepatic-impaired subjects; study terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Severe Hepatic Impairment | Phase 4 | Status: TERMINATED | Results posted: 2023-11-30